[{"data":1,"prerenderedAt":198},["ShallowReactive",2],{"drug-nadolol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":51,"contraindications":94,"warnings":104,"renal":111,"monitoring":120,"interactions":121,"review":122,"examples":125,"atc":135,"iran":137,"usApproval":149,"links":155,"populations":171},"nadolol",1,{"fa":7,"en":8},"نادولول","Nadolol","cardiovascular",{"fa":11,"en":12},"بتابلاکر غیرانتخابی","Non-selective beta-blocker",[14],{"name":15,"market":16},"Corgard","US",[18,19,7],"corgard","کورگارد",[21,35,43],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-20","tablet","oral","20 mg tablet (scored)",{"amount":27,"unit":28,"perUnit":23,"scored":29},20,"mg",true,[16],[32],{"source":33,"section":34},"fda-nadolol","How Supplied",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"tab-40","40 mg tablet (scored)",{"amount":39,"unit":28,"perUnit":23,"scored":29},40,[16],[42],{"source":33,"section":34},{"id":44,"form":23,"route":24,"label":45,"concentration":46,"markets":48,"refs":49},"tab-80","80 mg tablet (scored)",{"amount":47,"unit":28,"perUnit":23,"scored":29},80,[16],[50],{"source":33,"section":34},[52,79],{"id":53,"disease":53,"label":54,"population":57,"type":61,"unit":28,"dose":62,"refs":63,"limits":66,"notes":70},"angina",{"fa":55,"en":56},"آنژین صدری — شروع ۴۰ mg یک بار؛ نگهدارنده ۴۰ تا ۸۰ mg (تا ۲۴۰)","Angina — start 40 mg once daily; maintenance 40–80 mg (up to 240)",{"minAge":58},{"value":59,"unit":60},18,"year","fixed",{"perDose":39,"perDoseMax":47,"dosesPerDay":5},[64],{"source":33,"section":65},"Dosage and Administration",{"maxPerDay":67,"refs":68},240,[69],{"source":33,"section":65},[71],{"text":72,"refs":75},{"fa":73,"en":74},"افزایش ۴۰ تا ۸۰ mg هر ۳ تا ۷ روز. قطع ناگهانی خطر تشدید آنژین و MI دارد.","Increase by 40–80 mg every 3–7 days. Abrupt cessation may exacerbate angina and MI.",[76,77],{"source":33,"section":65},{"source":33,"section":78},"Warnings",{"id":80,"disease":81,"label":82,"population":85,"type":61,"unit":28,"dose":87,"refs":88,"limits":90},"htn","hypertension",{"fa":83,"en":84},"فشار خون — شروع ۴۰ mg یک بار؛ نگهدارنده ۴۰ تا ۸۰ mg (تا ۳۲۰)","Hypertension — start 40 mg once daily; maintenance 40–80 mg (up to 320)",{"minAge":86},{"value":59,"unit":60},{"perDose":39,"perDoseMax":47,"dosesPerDay":5},[89],{"source":33,"section":65},{"maxPerDay":91,"refs":92},320,[93],{"source":33,"section":65},[95],{"id":96,"severity":97,"text":98,"refs":101},"ci","block",{"fa":99,"en":100},"آسم برونشیال؛ برادی‌کاردی سینوسی و بلوک بالاتر از درجه ۱؛ شوک کاردیوژنیک؛ نارسایی آشکار قلب.","Bronchial asthma; sinus bradycardia and greater than first-degree block; cardiogenic shock; overt cardiac failure.",[102],{"source":33,"section":103},"Contraindications",[105],{"text":106,"refs":109},{"fa":107,"en":108},"قطع ناگهانی — تشدید آنژین و گاه MI؛ کاهش تدریجی.","Abrupt withdrawal — exacerbated angina and occasionally MI; taper gradually.",[110],{"source":33,"section":78},[112],{"egfrBelow":113,"severity":114,"text":115,"refs":118},50,"warn",{"fa":116,"en":117},"نارسایی کلیه: افزایش فاصله دوز طبق ClCr (برچسب).","Renal failure: extend the dosing interval by CrCl (per label).",[119],{"source":33,"section":65},[],[],{"status":123,"reviewer":124,"date":124},"unverified",null,[126,131],{"regimen":53,"formulation":36,"input":127,"expect":130},{"ageYears":128,"weightKg":129},60,75,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":47},{"regimen":80,"formulation":36,"input":132,"expect":134},{"ageYears":133,"weightKg":47},55,{"perDose":39,"tabletsPerDoseRounded":5,"upperPerDose":47},[136],"C07AA12",{"status":138,"forms":139,"refs":144},"registered",[140],{"code":141,"en":142,"fa":143},"01604","NADOLOL 80 MG TAB","قرص نادولول ۸۰ میلی‌گرم",[145],{"source":146,"section":147,"url":148},"darooyab-generic","G-1781\u002FNadolol","https:\u002F\u002Fwww.darooyab.ir\u002FG-1781\u002FNadolol",{"kind":150,"refs":151,"id":154},"ANDA",[152],{"source":33,"section":153},"SPL approval \u002F marketing category","ANDA201893",[156,159,163,166,169],{"kind":157,"url":158,"label":154},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=201893",{"kind":160,"url":161,"label":162},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=f11553f1-18ec-41b0-a7ad-1c9f21ef2c9f","FDA Nadolol",{"kind":164,"url":165,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682666.html",{"kind":167,"url":168,"label":136},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C07AA12",{"kind":170,"url":148,"label":8},"darooyab",{"pregnancy":172,"lactation":181,"pediatric":189},{"level":173,"text":174,"quote":177,"refs":178},"caution",{"fa":175,"en":176},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Nadolol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.",[179],{"source":33,"section":180},"PREGNANCY",{"level":173,"text":182,"quote":185,"refs":186},{"fa":183,"en":184},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Nadolol is excreted in human milk.",[187],{"source":33,"section":188},"NURSING MOTHERS",{"level":190,"text":191,"quote":194,"refs":195},"not-established",{"fa":192,"en":193},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[196],{"source":33,"section":197},"PEDIATRIC USE",1792191556557]